Merck-U02-Substudy 02D (Melanoma with Brain Metastasis)
What is the Purpose of this Study?
If you choose to join this study, during the screening period you will:
- Have physical exams
- Have blood draws
- Have other tests done to assess your eligibility
The screening period will last for about one month.
If you are found to be eligible, you will continue on to the study dosing period. During this period, you will:
- Be randomly assigned (like a coin flip) to 1 of 2 groups
-- Group 1 will get MK-1308A (MK-1308 + pembrolizumab) and lenvatinib
-- Group 2 will get pembrolizumab and lenvatinib
Pembrolizumab and MK-1308 are given as intravenous (IV) infusions. Lenvatinib is a capsule that you take by mouth.
Who Can Participate in this Study?
Adults ages 18+ who:
- Are diagnosed with stage IV melanoma
- Have metastasis to the brain
- Have not received more than 3 lines of previous therapies
For more information about who can join this study, please contact the study team at firstname.lastname@example.org.
What is Involved?
We are doing this study to find out if different combinations of experimental drugs are safe and effective treatments for melanoma that has spread to the brain. We also want to know if there are biological markers, like your genes, that can help us predict how well the study drugs might work in the body to treat MBM.
Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in
Participants With Melanoma-Substudy 02D